Enfuvirtide and cutaneous injection-site reactions

Journal of Drugs in Dermatology

Volumn 11, Issue 10, 2012, Pages

  Mirza, Raul A ^a   Turiansky, George W ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE;

ARTICLE; COLLAGEN DEGRADATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; EOSINOPHILIA; GRANULOMATOUS INFLAMMATION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE REACTION; PATIENT COMPLIANCE; PRURITUS; SIDE EFFECT; URTICARIA;

CYSTS; DRUG ERUPTIONS; EPIDERMAL CYST; ERYTHEMA; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; PATIENT SELECTION; PEPTIDE FRAGMENTS; PRURITUS;

EID: 84868624085     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Mohanty U, Dixit NM. Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor. J Theor Biol. 2008;251(3):541-551.
2. English M. Fuzeon. The AIDS Beacon Web site. Available at: http://www.aidsbeacon.com/resources/2009/07/07/fuzeon/. Accessed August 15, 2012.
3. Lalezari JP, Henry K, O'Hearn M, et al; TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348(22):2175-2185. (Pubitemid 36618128)
4. Maggi P, Ladisa N, Cinori E, Altobella A, Pastore G, Filotico R. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother. 2004;53(4):678-681. (Pubitemid 38499790)
5. Genentech, USA, Inc, Trimeris, Inc. The FUZEON difference. FUZEON Web site. Available at: http://www.fuzeon.com/hcp/the-fuzeon-difference.aspx. Accessed August 15, 2012.
6. FDA Approved Drug Products. US FDA label approved on December 22, 2009, for Fuzeon NDA # 021481. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/label/2009/021481s017lbl.pdf. Accessed August 15, 2012.
7. Lexi-Comp OnlineTM, Lexi-Drugs OnlineTM, Hudson, OH: Lexi-Comp, Inc.; February 2010. Available at: https://online.lexi.com/lco/action/doc/retrieve/ docid/patch-f/6819 Accessed August 28, 2012.
8. Maggi P, Filotico R, Bonora S, et al. Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug? Clin Drug Investig. 2008;28(5):305-311. (Pubitemid 351521383)
9. Lalezari JP, Patel IH, Zhang X, et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol. 2003;28(2):217-222. (Pubitemid 37040873)
10. Mole L. Enfuvirtide (Fuzeon™) Criteria for Use. VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel. April 2006. Available at: http://www.pbm.va.gov/Clinical%20Guidance/ Criteria%20For%20Use/Enfuvirtide,%20Criteria%20for%20Formulary%20Use.pdf. Accessed August 15, 2012.
11. Ball RA, Kinchelow T; ISR Substudy Group. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol. 2003;49(5):826-831. (Pubitemid 37314869)
12. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with immunodeficiency virus infection. J Antimicrob Chemother. 2008;62(5):879-888.